---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-25-000024"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T08:04:55.057682+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact

## Summary
- Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.
- Full-year 2024 net sales $2,519.4M (+60.6% YoY); GAAP net income $103.0M; GAAP EPS $0.75, non-GAAP EPS $3.04.
- 2025 stand-alone guidance: revenue $2.66-2.69B, non-GAAP EPS $3.40-3.50; with Nevro acquisition (close late Q2): revenue $2.80-2.90B, non-GAAP EPS $3.10-3.40.
- Q4 non-GAAP adjusted EBITDA $196.9M (30.0% of sales); full-year operating cash flow $520.6M, free cash flow $405.2M.
- CEO cites record product launches and integration progress; team executed on strategic objectives to drive value.

## SEC filing metadata
- accession: 0001562762-25-000024
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276225000024/0001562762-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276225000024/gmed-20250220x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-25-000024
- JSON: https://secwatch.observer/filing/0001562762-25-000024.json
- Plain text: https://secwatch.observer/filing/0001562762-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.